Minerva Neurosciences, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Minerva Neurosciences, Inc. (NERV) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-11
- Minerva Neurosciences, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $3.60M.
- Minerva Neurosciences, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$800.00K, a 111.76% decline from fiscal 2023.
- Minerva Neurosciences, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $6.80M, a 22.73% decline from fiscal 2022.
- Minerva Neurosciences, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $8.80M, a 14.56% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|
| 2025-12-31 | $3.60M 10-K · filed 2026-03-11 | |
| 2024-12-31 | -$800.00K 10-K · filed 2026-03-11 | |
| 2023-12-31 | $6.80M 10-K · filed 2024-02-22 | $6.80M 10-K · filed 2025-02-25 |
| 2022-12-31 | $8.80M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $10.30M 10-K · filed 2023-03-08 | |
| 2020-12-31 | $1.30M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $17.60M 10-K · filed 2021-03-08 | |
| 2018-12-31 | $12.80M 10-K · filed 2020-03-09 | |
| 2017-12-31 | -$9.90M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $11.90M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $10.30M 10-K · filed 2017-03-13 | |
| 2014-12-31 | $20.70M 10-K · filed 2016-03-14 | |
| 2013-12-31 | $3.30M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |